ENDURE: Engagement with the Novel Therapies and Decision Making Through Breast Cancer Education May 5th 2017

The goal of this educational activity to improve healthcare providers’ knowledge of a new novel treatment strategy for patients with breast cancer.  

Course details

  • Activity type: Course
  • ACPE: 1.50
  • ANCC: 1.50
  • JA Credit: 1.50
  • Registration Opens: Fri, May 05 2017
  • Registration Expires: Fri, May 04 2018
  • Cost: $0.00


Hyatt Regency Denver Convention Center
Centennial F-G 650
650 15th Street
Denver , CO

Learning objectives

After completing this activity, the participant should be better able to:

  • Review current research on the use of CDK 4/6 inhibitors for breast cancer patients, including  pre-clinical data, biomarker targets and sensitivity and resistance mechanisms
  • Discuss the MOA of CDK 4/6 inhibitors
  • Review clinical trial data on CDK 4/6 inhibitors, including efficacy and safety data
  • Identify appropriate patient selection for the use of CDK 4/6 inhibitors
  • Review the toxicity profiles of CDK 4/6 inhibitors
  • Apply strategies to manage neutropenia and other adverse events
  • Discuss existing and emerging clinical trial data associated with adverse events of combination  therapies using CDK 4/6 inhibitors
  • Discuss ways to enhance clinician/patient communication to improve patient outcomes
  • Apply shared decision-making strategies in the management of patients with breast cancer

Target Audience

This activity opens on May 5th, 2017.